We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Uqora Supplements in Women With UTIs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04024046
Recruitment Status : Terminated (Sponsor Decision)
First Posted : July 18, 2019
Last Update Posted : September 27, 2022
Sponsor:
Collaborator:
Uqora, Inc.
Information provided by (Responsible Party):
Hawthorne Effect Inc.

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a virtual study which will invite females over the age of 18 who have had 2 or more UTIs in the past 6 months to participate. The investigators are looking at the impact of a daily dietary supplement with the recurrence of UTIs. Participants will be blinded and randomized randomized into the Control Group or Groups 1 or 2. Control Group will receive a Placebo Drink-Mix and Placebo Capsules. Group 1 will receive the Uqora Drink-Mix and Placebo Capsules. Group 2 will receive the Uqora Drink-Mix and Uqora Capsules. Each group will receive 180 day supply of the products.

Condition or disease Intervention/treatment
Urinary Tract Infections Dietary Supplement: Uqora Dietary Supplement: Group1 Dietary Supplement: Group 2

Detailed Description:

Urinary Track Infections (UTIs) are the second most common infection in the United Stated. There is growing concern about the amount of antibiotic use and drug resistance. Patients with frequent UTIs are encouraged to keep well hydrated. Some are encouraged to drink cranberry juice or cranberry extract. In 2016 a published study demonstrated no difference. The investigators hypothesize that the Uqora dietary supplement will decrease the frequency of UTIs.

The study was designed as a prospective randomized blinded study. Results will be patient reported results along with any confirmation of a documented UTI. Participants will be asked to keep a weekly diary logging the supplement intake. The participant will also be asked to complete the King's Health Questionnaire, a urinary health questionnaire and quality of life. The data will be entered by the participant into a portal using a personalized login and password.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 360 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Evaluation of the Impact of the Uqora Dietary Supplement Products on Urinary Tract Infection (UTI) Incidence in Women With Recurring UTIs
Actual Study Start Date : April 18, 2019
Actual Primary Completion Date : September 16, 2020
Actual Study Completion Date : September 16, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Control - Placebo
  1. Placebo Drink-Mix Daily for 180 days
  2. Placebo Capsules Daily for 180 days
 Dietary Supplement: Uqora
Participants will receive 1 Placebo Drink-Mix and 2 Placebo Capsules Daily
Other Name: Placebo
Group 1
  1. Uqora Drink-Mix Daily for 180 days
  2. Placebo Capsules Daily for 180 days
 Dietary Supplement: Group1
Participants will receive 1 Uqora Drink-Mix and 2 Placebo Capsules Daily
Group 2
  1. Uqora Drink-Mix Daily for 180 days
  2. Uqora Capsules Daily for 180 days
 Dietary Supplement: Group 2
Participants will receive 1 Uqora Drink-Mix and 2 Uqora Capsules Daily


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Recurrence of UTIs at six-months [ Time Frame: 6-months ]
    A UTI is defined by the receipt of a prescription of antibiotics for treatment


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Female gender as diagnosed at birth without any alterations at the time of enrollment
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The study will consist of 360 female subjects aged 18 and older with at least 2 UTIs in the past 6 months. The subjects will be otherwise healthy. The geography of subject enrollment will be spread across the United States.
Criteria

Inclusion Criteria:

  • Is female
  • Is 18 years of age or older
  • Is able to swallow pills
  • Has been treated with antibiotics for 2 or more UTIs in the past 6 months
  • Is otherwise in good health Subjects will be deemed to be in good health if they do not report any of the existing medical conditions asked about in the screening questionnaire.

Exclusion Criteria:

  • Has any of the following medical conditions: multiple sclerosis; diabetes; chronic kidney stones ○ Subjects with multiple sclerosis, diabetes, and/ or chronic kidney stones will be excluded from the study because these subjects are more likely to have complicated UTIs.
  • Uses a wheelchair ○ Subjects that use a wheelchair will be excluded from the study as these subjects are more likely to have complicated UTIs.

  • Regularly uses a catheter

    ○ Subjects that use catheters will be excluded from the study as these subjects are more likely to have complicated UTIs.

  • Is pregnant

    ○ Pregnant women and women that become pregnant will be excluded from the study because of an increased likelihood these subjects will drop out from the study on recommendation from their physicians or other healthcare provider.

  • Is currently taking Uqora brand products for UTI prevention

    ○ Subjects will be asked if they are currently taking other products for UTI prevention. If the subject indicates she is currently taking a Uqora product, she will be excluded from the study. If the subject indicates she is taking additional products for prevention (not Uqora products), she will not be excluded from the study and she will be eligible to be enrolled and randomly assigned into 1 of the 3 groups.

  • Is currently taking antibiotics prophylactically for the purpose of UTI prevention ○ These subjects will be excluded from the study because they have been instructed by their physician or other healthcare provider to take antibiotics on an ongoing basis, which would have a significant impact on the recurrence of UTIs.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04024046


Locations
Layout table for location information
United States, California
Uqora, Inc.
San Diego, California, United States, 92116
Sponsors and Collaborators
Hawthorne Effect Inc.
Uqora, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Martina Speight, MSN, FNP-BC Hawthorne Effect Inc.
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications of Results:
Porru, D et al. "Oral D-Mannose in recurrent urinary tract infections in women - a pilot study". Journal of Clinical Urology. Volume 7, Issue 3. 2014.
Yaxley, Julian. "Alkalization of urine in patients with infections of the urinary tract." British Journal of Medicine and Medical Research. 2016.
Ku, Ja Hyeon and Oh, Seung-June. Comparison of Three Quality of Life Questionnaires in Urinary Incontinence. Springer Science and Business Media. 2010.

Layout table for additonal information
Responsible Party: Hawthorne Effect Inc.
ClinicalTrials.gov Identifier: NCT04024046    
Other Study ID Numbers: Pro00034128
First Posted: July 18, 2019    Key Record Dates
Last Update Posted: September 27, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The data will be owned by the Sponsor, Uqora Inc. The data will be collected, analyzed and given to the sponsor.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Urinary Tract Infections
Urologic Diseases